Studies on human tumoroids showed divergent results, demonstrating either a tumor‐suppressive response and minimal changes in EMT marker gene expression [4] or KRAS‐dependent resistance to TGF‐β treatment through downregulation of the pro‐apoptotic protein BIM [13]. The gene discussed is KRAS; the disease is neoplasm.